Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

30 Apr 2024

Abstract excerpt

PURPOSE: Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma. However, mechanisms underlying primary and acquired resistance remain poorly understood. EXPERIMENTAL DESIGN: The anti-multiple myeloma activity of teclistamab and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38687588
DOI: 10.1158/1078-0432.ccr-23-3333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaPMID 38687588Read ↗

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity Read ↗

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read ↗

Acquired resistance to bispecific antibodies by genetic or epigenetic inactivation of the target in multiple myelomaSemantic proximity Read ↗

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple MyelomaSemantic proximity Read ↗

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myelomaSemantic proximity Read ↗

Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivationSemantic proximity Read ↗

PD1+TIGIT+2B4+KLRG1+ cells might underlie T-cell dysfunction in patients treated with BCMA-directed CAR-T therapySemantic proximity Read ↗

Teclistamab: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.